CDK7-IN-2 |
| Catalog No.GC63980 |
CDK7-IN-2는 CDK7의 강력한 억제제입니다. CDK7은 세포 주기와 전사 활성의 시간적 조절과 관련이 있습니다. CDK7은 RNA 중합효소 II(RNAPII)의 Rbpl 소단위의 인산화에 의한 전사 개시 과정에 연루되어 있습니다. CDK7은 암 질환, 특히 공격적이고 치료하기 어려운 암의 연구에 대한 잠재력이 있습니다(특허 WO2019099298A1, 화합물 1에서 추출).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2326428-19-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1].
[1]. David Andrew Coates, et al. Compounds useful for inhibiting cdk7. Patent WO2019099298A1.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *